JAM-B/VE-JAM Antibody (150005)

Recombinant Mouse JAM‑B/VE‑JAM Fc Chimera (Catalog # 988-VJ), immobilized onto a microplate previously coated with Goat Anti-Human IgG Fc (Catalog # G‑102‑C), supports the adhesion of the J45.01 human acute lymphoblastic leukemia T lymphocyte cell line in a dose-dependent manner (orange line), as measured by endogenous cellular lysosomal acid phosphatase activity. Adhesion elicited by Recombinant Mouse JAM‑B/VE‑JAM Fc Chimera (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Rat Anti-Mouse JAM-B/VE-JAM Monoclonal Antibody (Catalog # MAB9881). The ND50 is typically 0.1-0.5 µg/mL.

• Reactivity: Mu
• Applications: B/N
• Clone: 150005
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Unconjugated

JAM-B/VE-JAM Antibody (150005) Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse JAM‑B/VE-JAM
  Phe29-Asn236 (predicted)
  Accession # Q9JI59
• Specificity: Detects mouse JAM‑B/VE-JAM in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant human JAM-1, -2, or -3 is observed.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat
• Gene: JAM2
• Purity Statement: Protein A or G purified from hybridoma culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 0.1-0.5 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for JAM-B/VE-JAM Antibody (150005)

• C21orf43
• CD322 antigen
• CD322
• JAM2
• JAMB
• JAM-B
• JAM-BJAM-IT/VE-JAM
• junctional adhesion molecule 2JAM-2
• junctional adhesion molecule B
• PRO245
• Vascular endothelial junction-associated molecule
• VE-JAM
• VE-JAMVEJAMCD322

Background

The family of juctional adhesion molecules (JAM), comprising at least three members, are type I transmembrane receptors belonging to the immunoglobulin (Ig) superfamily (1, 2). These proteins are localized in the tight junctions between endothelial cells or epithelial cells. Some family members are also found on blood leukocytes and platelets. JAM-B, alternatively named vascular endothelial JAM (VE-JAM), is expressed prominently on high endothelial venules of lymphoid organs where it is localized to the intercellular boundaries of high endothelial cells. It is also expressed on the endothelium of a variety of non-lymphoid organs, especially the heart and placenta (2, 3, 5). Mouse JAM-B/VE-JAM cDNA predicts a 298 amino acid (aa) precursor protein with a putative 28 aa signal peptide, a 209 aa extracellular region containing two Ig domains, a 23 aa transmembrane domain and a 38 aa cytoplasmic domain containing a PDZ-binding motif and a PKC phosphorylation site (2, 3). Mouse JAM-B shares approximately 79% aa sequence homology with its human homologue. It also shares approximately 35% aa sequence homology with mouse JAM-A or JAM‑C. JAM-B exhibits homotypic interactions, as well as heterotypic interactions with JAM‑C, but not JAM-A (4, 5, 7). It is also a ligand for the Integrin alpha4beta1. However, the JAM-B/alpha4beta1 interaction is facilitated only after prior adhesion of JAM-B to JAM‑C (6). Through its heterotypic interactions with JAM‑C, JAM-B is an adhesive ligand for T, NK, and dendritic cells, and may play a role in regulating leukocyte transmigration (5).

1. Chavakis, T. et al. (2003) Thromb. Haemost. 89:13. 
2. Aurand-Lions, M. et al. (2001) Blood 98:3699.
3. Palmeri, A. et al. (2000) J. Biol. Chem. 275:19139.
4. Cunnigham, S. et al. (2000) J. Biol. Chem. 275:34750.
5. Liang, T. et al. (2002) J. Immunol. 168:1618.
6. Cunningham, A. et al. (2002) J Biol. Chem. 277:27589.
7. Arrate, M. et al. (2001) J. Biol. Chem. 276:45826.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for JAM-B/VE-JAM Antibody (MAB9881)(3)

Publications using MAB9881

• Somatodendritic Expression of JAM2 Inhibits Oligodendrocyte Myelination Neuron, 2016-08-04;91(4):824-836. 2016-08-04 [PMID: 27499083]
• Martin-Blondel G, Pignolet B, Tietz S, Yshii L, Gebauer C, Perinat T, Van Weddingen I, Blatti C, Engelhardt B, Liblau R Migration of encephalitogenic CD8 T cells into the central nervous system is dependent on the alpha4beta1-integrin. Eur J Immunol, 2015-10-06;45(12):3302-12. 2015-10-06 [PMID: 26358409] (In Vivo, Mouse)
• Ludwig RJ, Hardt K, Hatting M, Bistrian R, Diehl S, Radeke HH, Podda M, Schon MP, Kaufmann R, Henschler R, Pfeilschifter JM, Santoso S, Boehncke WH Junctional adhesion molecule (JAM)-B supports lymphocyte rolling and adhesion through interaction with alpha4beta1 integrin. Immunology, 2009-10-01;128(2):196-205. 2009-10-01 [PMID: 19740376] (Neutralization, Mouse)

Bioinformatics

• Gene Symbol: JAM2
• Uniprot:
  • Q9JI59()